Cargando…
Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma
INTRODUCTION: Granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma is rare, with a poor prognosis. Advanced urothelial carcinoma is currently treated with immune checkpoint inhibitors, whose efficacy for granulocyte colony‐stimulating factor‐producing upper urinar...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888018/ https://www.ncbi.nlm.nih.gov/pubmed/35252793 http://dx.doi.org/10.1002/iju5.12406 |
_version_ | 1784661030546178048 |
---|---|
author | Takeda, Hiroki Matsumoto, Ryuji Takakuwa, Emi Hori, Kanta Moriguchi, Takuya Yamada, Shuhei Kikuchi, Hiroshi Osawa, Takahiro Abe, Takashige Shinohara, Nobuo |
author_facet | Takeda, Hiroki Matsumoto, Ryuji Takakuwa, Emi Hori, Kanta Moriguchi, Takuya Yamada, Shuhei Kikuchi, Hiroshi Osawa, Takahiro Abe, Takashige Shinohara, Nobuo |
author_sort | Takeda, Hiroki |
collection | PubMed |
description | INTRODUCTION: Granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma is rare, with a poor prognosis. Advanced urothelial carcinoma is currently treated with immune checkpoint inhibitors, whose efficacy for granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma remains unclear. CASE PRESENTATION: A 66‐year‐old male diagnosed with clinical stage T3N1M0 urothelial carcinoma of the right ureter with giant hydronephrosis underwent right radical nephroureterectomy. Local recurrence, leukocytosis, and elevated serum granulocyte colony‐stimulating factor levels were observed approximately 3 months after surgery. Chemotherapy was started but failed to control the disease. Therefore, pembrolizumab was chosen as the second‐line treatment. After this treatment, the blood leukocyte count rapidly normalized, and a clinically favorable response was achieved. There was no recurrence 10 months after the beginning of pembrolizumab treatment, which is still ongoing. CONCLUSION: Pembrolizumab may be a treatment option for advanced granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma. |
format | Online Article Text |
id | pubmed-8888018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88880182022-03-04 Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma Takeda, Hiroki Matsumoto, Ryuji Takakuwa, Emi Hori, Kanta Moriguchi, Takuya Yamada, Shuhei Kikuchi, Hiroshi Osawa, Takahiro Abe, Takashige Shinohara, Nobuo IJU Case Rep Case Reports INTRODUCTION: Granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma is rare, with a poor prognosis. Advanced urothelial carcinoma is currently treated with immune checkpoint inhibitors, whose efficacy for granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma remains unclear. CASE PRESENTATION: A 66‐year‐old male diagnosed with clinical stage T3N1M0 urothelial carcinoma of the right ureter with giant hydronephrosis underwent right radical nephroureterectomy. Local recurrence, leukocytosis, and elevated serum granulocyte colony‐stimulating factor levels were observed approximately 3 months after surgery. Chemotherapy was started but failed to control the disease. Therefore, pembrolizumab was chosen as the second‐line treatment. After this treatment, the blood leukocyte count rapidly normalized, and a clinically favorable response was achieved. There was no recurrence 10 months after the beginning of pembrolizumab treatment, which is still ongoing. CONCLUSION: Pembrolizumab may be a treatment option for advanced granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma. John Wiley and Sons Inc. 2021-12-17 /pmc/articles/PMC8888018/ /pubmed/35252793 http://dx.doi.org/10.1002/iju5.12406 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Takeda, Hiroki Matsumoto, Ryuji Takakuwa, Emi Hori, Kanta Moriguchi, Takuya Yamada, Shuhei Kikuchi, Hiroshi Osawa, Takahiro Abe, Takashige Shinohara, Nobuo Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title | Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title_full | Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title_fullStr | Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title_full_unstemmed | Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title_short | Favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
title_sort | favorable response to pembrolizumab in granulocyte colony‐stimulating factor‐producing upper urinary tract urothelial carcinoma |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888018/ https://www.ncbi.nlm.nih.gov/pubmed/35252793 http://dx.doi.org/10.1002/iju5.12406 |
work_keys_str_mv | AT takedahiroki favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT matsumotoryuji favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT takakuwaemi favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT horikanta favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT moriguchitakuya favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT yamadashuhei favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT kikuchihiroshi favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT osawatakahiro favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT abetakashige favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma AT shinoharanobuo favorableresponsetopembrolizumabingranulocytecolonystimulatingfactorproducingupperurinarytracturothelialcarcinoma |